Ascentage Pharma Group International

6855

KYG0519B1023

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 04:09:01 2025-06-16 am EDT			5-day change	1st Jan Change
63.20 ^HKD	+1.36%		+7.39%	+39.05%

Jun. 03	Ascentage Pharma Group International Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors	CI
Jun. 03	Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Report	CI

Ascentage Drugs Included in Chinese Society of Clinical Oncology Guidelines; Shares Surge 13%

Published on 04/21/2025 at 23:35, updated on 04/21/2025 at 23:36

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Ascentage Pharma Group International

Ascentage Pharma Group International Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors	Jun. 03	CI
Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Report	Jun. 03	CI
Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025	May. 22	CI
Ascentage Pharma Presents Results of Five Preclinical Studies for Anti-Cancer Drugs	Apr. 29	MT
Ascentage Pharma Presents Results from Five Preclinical Studies at 2025 American Association of Cancer Research Annual Meeting, Highlighting Strong Synergistic Effects of Olverembatinib Combined with Lisaftoclax	Apr. 28	CI
Ascentage Drugs Included in Chinese Society of Clinical Oncology Guidelines; Shares Surge 13%	Apr. 21	MT
Ascentage Pharma Says 2 Investigational Drugs Added to 2025 CSCO Guidelines	Apr. 21	MT
Ascentage Pharma Announces Inclusion of Lisaftoclax and Olverembatinib in Chinese Society of Clinical Oncology 2025 Guidelines	Apr. 21	CI
Ascentage Pharma Trustee Buys HK$1.8 Million Shares	Apr. 09	MT
SPDB International HK Starts Ascentage Pharma Group International at Buy with HK$57 Price Target	Apr. 03	MT
Ascentage Pharma Narrows Loss in 2024	Mar. 28	MT
Sector Update: Health Care Stocks Flat to Higher Premarket Thursday	Mar. 27	MT
Ascentage Pharma Group International Says Revenue In 2024 Increased 342% Year-Over-Year	Mar. 27	RE
Ascentage Pharma Group International, 2024 Earnings Call, Mar 27, 2025	Mar. 27
Ascentage Pharma Reports Full Year 2024 Unaudited Financial Results And Business Updates	Mar. 27	RE
Ascentage Pharma Group's 2024 Loss Narrows, Revenue Rises	Mar. 27	MT
Earnings Flash (AAPG) Ascentage Pharma Posts 2024 Revenue 980.7M Chinese Renminbi	Mar. 27	MT
Earnings Flash (AAPG) Ascentage Pharma Group Posts Full Year 2024 Loss of 1.34 Chinese Renminbi a Share	Mar. 27	MT
Ascentage Pharma Group International Reports Earnings Results for the Full Year Ended December 31, 2024	Mar. 27	CI
Ascentage Pharma to Present Five Preclinical Studies from Innovative Pipeline at American Association of Cancer Research Annual Meeting 2025	Mar. 25	CI
Ascentage Pharma's Olverembatinib Granted Breakthrough Therapy Designation in China	Mar. 06	MT
China Designates Ascentage's Olverembatinib Cancer Therapy as Breakthrough Therapy	Mar. 06	MT
Ascentage Pharma Group International Says Olverembatinib Given Breakthrough Therapy Designation	Mar. 05	RE
Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)	Mar. 05	RE
Ascentage Pharma Receives Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia	Mar. 05	CI

Chart Ascentage Pharma Group International

Duration

Period

Chart Ascentage Pharma Group International

6855: Dynamic Chart

Ascentage Pharma Group International is an investment holding company principally engaged in developing novel small therapies for cancers, hepatitis B virus (HBV) and certain age-related diseases. The Company focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The Company's main products include the next-generation kinase inhibitor: HQP1351 and apoptosis targeted drugs APG-1252, APG2575, APG-115 and so on. The Company conducts businesses within the domestic market and to overseas markets, including the United States.

Employees

567

Sector

Biotechnology & Medical Research

Calendar

Aug. 25 - Q2 2025 Earnings Release (Projected)

More about the company